Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Bernhardt S, Bayerlová M, Vetter M, Wachter A, Mitra D, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Thomssen C, Korf U, Beissbarth T, Wiemann S, Kantelhardt EJ. Bernhardt S, et al. Among authors: lantzsch t. Breast Cancer Res. 2017 Oct 11;19(1):112. doi: 10.1186/s13058-017-0905-7. Breast Cancer Res. 2017. PMID: 29020998 Free PMC article. Clinical Trial.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Sertoli-Leydig cell tumor.
Lantzsch T, Stoerer S, Lawrenz K, Buchmann J, Strauss HG, Koelbl H. Lantzsch T, et al. Arch Gynecol Obstet. 2001 Jan;264(4):206-8. doi: 10.1007/s004040000114. Arch Gynecol Obstet. 2001. PMID: 11205710
Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS).
Kluttig A, Trocchi P, Heinig A, Holzhausen HJ, Taege C, Hauptmann S, Boecker W, Decker T, Loening T, Schmidt-Pokrzywniak A, Thomssen C, Lantzsch T, Buchmann J, Stang A. Kluttig A, et al. Among authors: lantzsch t. BMC Cancer. 2007 Jun 14;7:100. doi: 10.1186/1471-2407-7-100. BMC Cancer. 2007. PMID: 17570833 Free PMC article.
Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients.
Bauer M, Kantelhardt EJ, Stiewe T, Nist A, Mernberger M, Politt K, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Wickenhauser C, Thomssen C, Bartel F, Vetter M. Bauer M, et al. Among authors: lantzsch t. Oncotarget. 2019 Mar 8;10(20):1975-1992. doi: 10.18632/oncotarget.26768. eCollection 2019 Mar 8. Oncotarget. 2019. PMID: 30956778 Free PMC article.
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.
Hartung C, Porsch M, Stückrath K, Kaufhold S, Staege MS, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Pöhler M, Weigert E, Buchmann J, Bürrig KF, Schüler K, Bethmann D, Große I, Kantelhardt EJ, Thomssen C, Vetter M. Hartung C, et al. Among authors: lantzsch t. Breast Care (Basel). 2021 Dec;16(6):637-647. doi: 10.1159/000519255. Epub 2021 Oct 19. Breast Care (Basel). 2021. PMID: 35082572 Free PMC article.
31 results